Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma

  • Martina Mayr1,
  • Karen Becker2,
  • Nadine Schulte3,
  • Sebastian Belle3,
  • Ralf Hofheinz4,
  • Annekatrin Krause5,
  • Roland M Schmid1,
  • Christoph Röcken6 and
  • Matthias P Ebert3Email author
BMC Cancer201212:587

DOI: 10.1186/1471-2407-12-587

Received: 12 April 2012

Accepted: 19 November 2012

Published: 10 December 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
12 Apr 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
15 Aug 2012 Reviewed Reviewer Report - Salah-Eddin Al-Batran
31 Aug 2012 Reviewed Reviewer Report - Peter Reichardt
29 Oct 2012 Author responded Author comments - Martina Mayr
Resubmission - Version 4
29 Oct 2012 Submitted Manuscript version 4
Publishing
19 Nov 2012 Editorially accepted
10 Dec 2012 Article published 10.1186/1471-2407-12-587

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Internal Medicine II, Klinikum Rechts der Isar, Technical University of Munich
(2)
Institute for Pathology, Klinikum Rechts der Isar, Technical University of Munich
(3)
Department of Medicine II, University Hospital Mannheim, Ruprecht-Karls-Universität Heidelberg
(4)
Department of Medicine III, University Hospital Mannheim, Ruprecht-Karls-Universität Heidelberg
(5)
Novartis Pharma GmbH
(6)
Institute of Pathology, Christian-Albrechts Universität

Advertisement